AstraZeneca And Ironwood Link Up To Bring Linaclotide To China
This article was originally published in PharmAsia News
Executive Summary
Ironwood has signed AstraZeneca as its partner to develop and commercialize the irritable bowel syndrome drug linaclotide in China, though a Phase III trial has yet to start; Ironwood also announced it will commercialize AstraZeneca’s Nexium in the U.S.